Boomerang Therapeutics

Personalized Cancer Gene Therapy

Health Tech & Life Sciences
Non Active, Jan 2017

Company Overview

Snapshot

Founded in March 2015 by Ori Zelichov and Shai Duchin, Boomerang Therapeutics operates with 1–10 employees. The company is in the Pre-Funding stage and is recognized for its innovative work in genetic engineering, having won a top prize in Boston's Genetically Engineered Machine Competition in September 2015.

Business overview

Boomerang Therapeutics is a Health Tech & Life Sciences company focused on developing personalized cancer gene therapy. The company utilizes advanced gene editing tools, specifically CRISPR technology, to create genetic devices designed to eliminate cancer cells by activating suicide genes. This system can be tailored to the unique genetics of each patient's tumor, aiming to provide personalized treatment within the pharmaceutical and life sciences sectors.

Strategic signal

In February 2016, Boomerang Therapeutics was featured by Integrated DNA Technologies (IDT) for its work in targeting cancer treatments to cancer cells. This recognition highlights the company's progress in synthetic biology and its potential to innovate within the oncology space, signaling validation of its scientific approach to investors and the broader biotech community.

Company Intelligence Q&A

What is Boomerang Therapeutics' core focus?
Boomerang Therapeutics develops a genetic device for personalized cancer therapy, utilizing advanced gene editing tools to eliminate cancer cells by activating suicide genes.
When was Boomerang Therapeutics founded?
Boomerang Therapeutics was founded in March 2015.
Who are the founders of Boomerang Therapeutics?
The company was founded by Ori Zelichov and Shai Duchin.
What significant recognition did Boomerang Therapeutics receive in 2015?
In September 2015, Boomerang Therapeutics won a top prize in Boston's Genetically Engineered Machine Competition for its work in genetic engineering.
What technology does Boomerang Therapeutics primarily use?
Boomerang Therapeutics primarily uses CRISPR technology in its research and development of cancer treatments.